New and Evolving Therapeutic Targets in Lung Cancer: Expert Guidance in Incorporating Biomarker Testing to Deliver Precision Therapy

Listen to lung cancer experts Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer audience questions from a live CCO Webinar on biomarker testing and selecting targeted therapies for patients with advanced NSCLC.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP, FASCO Released: August 10, 2020

In this podcast episode, listen to lung cancer experts Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer audience questions from a live CCO Webinar on the topic of current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced NSCLC.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP, FASCO Released: August 10, 2020

In this pocast episode, listen to Helena A. Yu, MD, a medical oncologist, and Maria E. Arcila, MD, a molecular pathologist, discuss new data on actionable mutations and targeted therapies in NSCLC from ESMO 2020, including emerging therapeutic strategies targeting EGFR or KRAS G12C driver mutations.

Maria E. Arcila, MD Helena A. Yu, MD Released: December 21, 2020

In this podcast episode, listen to Nathan Pennell, MD, PhD, a medical oncologist, and Laura J. Tafe, MD, a molecular pathologist, as they answer questions from a clinician audience on best practices when testing for actionable mutations in NSCLC.

Nathan Pennell, MD, PhD Laura J. Tafe, MD Released: December 28, 2020

Key insights from our podcast featuring expert answers to questions on biomarker testing and selecting targeted therapies for patients with advanced NSCLC.

Highlights from our podcast featuring expert answers to questions on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in patients with advanced NSCLC.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP, FASCO Released: August 10, 2020

Highlights from our podcast featuring a medical oncologist and molecular pathologist discussing key data from ESMO 2020 informing precision medicine in NSCLC.

Maria E. Arcila, MD Helena A. Yu, MD Released: December 21, 2020

Highlights from our podcast featuring a medical oncologist and molecular pathologist discussing best practices when testing for actionable biomarkers in NSCLC.

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on new and emerging molecular targets guiding lung cancer management, from the role of biomarkers in immunotherapy to insights on NTRK fusions, RET fusions, and MET exon 14–skipping mutations.

Edward S. Kim, MD, FACP, FASCO
Program Director Leora Horn, MD, MSc, FRCPC Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: July 30, 2020 Expired: No longer available for credit

Current Status of Biomarker Testing in Lung Cancer (11 mins)

Recognizing Meaningful Responses With Targeted Agents in NSCLC and Low-Frequency Alterations (13 mins)

Therapeutic Targets Poised to Change Lung Cancer Care: New and Near-Future Predictive Biomarkers (18 mins)

Immune Checkpoint Inhibitors in Lung Cancer: Paving a New Avenue of Care (21 mins)

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert perspectives from a medical oncologist and molecular pathologist on biomarker testing and personalized therapy in lung cancer.

Nathan Pennell, MD, PhD Laura J. Tafe, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.0 Lifelong Learning MOC point Released: January 15, 2021 Expired: No longer available for credit

The Why and Who: Newly Available and Emerging Biomarkers for Lung Cancer (25 mins)

The How: Evidence-Based Testing Strategies to Detect Appropriate Gene Alterations (39 mins)

Download these slides to review expert insights from a medical oncologist on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC.

Nathan Pennell, MD, PhD Released: November 12, 2020

Download these slides to review expert insights from a pathologist on best practices for biomarker testing in the treatment of patients with advanced NSCLC.

Laura J. Tafe, MD Released: November 12, 2020

Download this short summary slideset of key takeaway points from a live CCO meeting series on the evolving use of biomarkers for precision therapy in lung cancer.

Eric Q. Konnick, MD, MS Nathan Pennell, MD, PhD Released: May 29, 2020

Download this short summary slideset of key takeaways from a live CCO Webinar focused on the use of new biomarkers critical to lung cancer care today.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP, FASCO Released: June 26, 2020

Download this short summary slideset of key takeaways from a live CCO Webinar featuring a medical oncologist and molecular pathologist discussing established and emerging biomarkers critical to optimal treatment of patients with advanced NSCLC.

Nathan Pennell, MD, PhD Laura J. Tafe, MD Released: November 24, 2020

Download these slides from our live meeting series to gain expert insights on how to integrate new and emerging molecular targets into the care of your patients with lung cancer.

Eric Q. Konnick, MD, MS Nathan Pennell, MD, PhD Released: May 5, 2020

Download this slideset on new and emerging molecular targets critical to lung cancer care, including expert insight on NTRK fusions, RET fusions, and MET exon 14 skipping mutations.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP, FASCO Released: June 25, 2020

Download this slideset for expert insights on the role of biomarkers in the optimal use of immunotherapy in the care of patients with NSCLC.

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP, FASCO Released: June 25, 2020

Which emerging biomarkers have the most potential to affect personalized care of our patients with NSCLC? Read my thoughts on testing for and targeting RET, MET exon 14, and more.

Todd M. Bauer, MD Released: February 28, 2020

As targeted therapy prolongs survival in our patients with oncogene-driven NSCLC, CNS metastases and leptomeningeal carcinomatosis are more likely to develop as part of the disease course. Read my thoughts on what factors I consider when treating these challenging disease manifestations.

Lyudmila Bazhenova, MD Released: April 28, 2020

Vamsidhar Velcheti, MD, provides his thoughts on the clinical implications of the recent approval of selpercatinib for RET fusion–positive NSCLC in this commentary.

Vamsidhar Velcheti, MD Released: June 25, 2020

Are you aware of emerging options for the treatment of advanced HER2-mutated NSCLC? Read my thoughts on a new therapy showing promise to improve outcomes in these patients.

Edward S. Kim, MD, FACP, FASCO Released: October 22, 2020

Download this PDF resource for clinical insights on new and established clinical biomarkers guiding NSCLC management, including best testing practices.

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with NSCLC with those of 5 renowned experts.

Matthew Gubens, MD, MS Wade T. Iams, MD, MSCI Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS H. Jack West, MD Released: January 12, 2021